Published in PLoS One on January 18, 2013
The multiple facets of drug resistance: one history, different approaches. J Exp Clin Cancer Res (2014) 1.25
Evaluation of therapeutics in three-dimensional cell culture systems by MALDI imaging mass spectrometry. Anal Chem (2013) 1.05
Advanced cell culture techniques for cancer drug discovery. Biology (Basel) (2014) 1.01
Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. BMC Cancer (2015) 0.88
Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One (2014) 0.87
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials (2015) 0.86
Safety of Nanoparticles in Medicine. Curr Drug Targets (2015) 0.83
Assessing Concordance of Drug-Induced Transcriptional Response in Rodent Liver and Cultured Hepatocytes. PLoS Comput Biol (2016) 0.83
Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS One (2013) 0.82
A computer-assisted 3D model for analyzing the aggregation of tumorigenic cells reveals specialized behaviors and unique cell types that facilitate aggregate coalescence. PLoS One (2015) 0.82
Drug penetration and metabolism in 3D cell cultures treated in a 3D printed fluidic device: assessment of irinotecan via MALDI imaging mass spectrometry. Proteomics (2016) 0.81
Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screening. Oncotarget (2015) 0.81
Culture models to define key mediators of cancer matrix remodeling. Front Oncol (2014) 0.81
Facile bench-top fabrication of enclosed circular microchannels provides 3D confined structure for growth of prostate epithelial cells. PLoS One (2014) 0.80
Liquid-based three-dimensional tumor models for cancer research and drug discovery. Exp Biol Med (Maywood) (2016) 0.78
Development of an acellular tumor extracellular matrix as a three-dimensional scaffold for tumor engineering. PLoS One (2014) 0.77
An interdisciplinary computational/experimental approach to evaluate drug-loaded gold nanoparticle tumor cytotoxicity. Nanomedicine (Lond) (2016) 0.76
The knee joint loose body as a source of viable autologous human chondrocytes. Eur J Histochem (2016) 0.76
Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents. Biotechnol Biotechnol Equip (2014) 0.75
In vitro evaluation of osteoprotegerin in chitosan for potential bone defect applications. PeerJ (2016) 0.75
High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models. Expert Opin Drug Discov (2015) 0.75
3D Cell Culture in Alginate Hydrogels. Microarrays (Basel) (2015) 0.75
From competency to dormancy: a 3D model to study cancer cells and drug responsiveness. J Transl Med (2016) 0.75
Inherent aggressive character of invasive and non-invasive cells dictates the in vitro migration pattern of multicellular spheroid. Sci Rep (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Taking cell-matrix adhesions to the third dimension. Science (2001) 15.21
Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol (2006) 8.81
Modeling tissue morphogenesis and cancer in 3D. Cell (2007) 7.49
Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods (2007) 7.43
The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol (2007) 7.38
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Engineering tumors with 3D scaffolds. Nat Methods (2007) 3.96
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med (1999) 2.92
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A (2011) 2.27
Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol (2005) 2.26
3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm (2008) 2.11
Cancer cell angiogenic capability is regulated by 3D culture and integrin engagement. Proc Natl Acad Sci U S A (2009) 2.07
Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol (2008) 1.99
Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials (2010) 1.95
Cancer stem cell: target for anti-cancer therapy. FASEB J (2007) 1.92
Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res (2007) 1.88
Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A (2003) 1.41
The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin Drug Discov (2012) 1.34
Simplifying the extracellular matrix for 3-D cell culture and tissue engineering: a pragmatic approach. J Cell Biochem (2007) 1.32
Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge. J Anat (2007) 1.31
The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials (2011) 1.30
Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery. Acc Chem Res (2007) 1.29
3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials (2011) 1.26
Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res (2010) 1.25
Engineering a scaffold-free 3D tumor model for in vitro drug penetration studies. Biomaterials (2009) 1.22
Three-dimensional chitosan scaffold-based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen. Biomaterials (2005) 1.17
The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One (2011) 1.11
Genome-wide gene expression analysis in cancer cells reveals 3D growth to affect ECM and processes associated with cell adhesion but not DNA repair. PLoS One (2012) 1.10
The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. J Transl Med (2012) 1.08
Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release (2010) 1.05
The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance. Cell Death Dis (2011) 0.97
β1 integrin: an emerging player in the modulation of tumorigenesis and response to therapy. Cell Adh Migr (2012) 0.94
The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res (2011) 0.93
Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res (2004) 0.93
Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. J Biosci Bioeng (2011) 0.92
Cancer stem cells: a new theory regarding a timeless disease. Chem Rev (2009) 0.90
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion. Int J Exp Pathol (2005) 0.85
A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol Vis (2012) 0.82
Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol (2010) 1.51
Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis (2010) 1.20
Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer (2010) 1.17
Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol (2008) 1.16
Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res (2009) 1.12
Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec. J Pharm Sci (2004) 1.11
Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: characterization of viscosity, in vitro drug release, droplet size, and dynamic surface tension. AAPS PharmSciTech (2005) 1.07
Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer. PLoS One (2011) 1.07
In vitro and in vivo evaluation of topical formulations of spantide II. AAPS PharmSciTech (2005) 1.06
Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials (2011) 1.06
Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J Control Release (2010) 1.05
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. Pharm Res (2006) 1.01
Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma. Clin Cancer Res (2004) 0.99
Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancer. Mol Cancer Ther (2010) 0.98
Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release (2012) 0.96
15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs (2007) 0.95
Effect of oleic acid modified polymeric bilayered nanoparticles on percutaneous delivery of spantide II and ketoprofen. J Control Release (2011) 0.94
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer (2006) 0.92
Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release (2013) 0.91
Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res (2004) 0.90
Skin permeation enhancement effect and skin irritation of saturated fatty alcohols. Int J Pharm (2002) 0.90
Effect of vehicles on the transdermal delivery of melatonin across porcine skin in vitro. J Control Release (2002) 0.90
Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application. Pharm Res (2012) 0.87
Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One (2014) 0.87
Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer. PLoS One (2011) 0.86
Evaluation of the Malvern Spraytec with inhalation cell for the measurement of particle size distribution from metered dose inhalers. J Pharm Sci (2004) 0.86
Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release (2013) 0.85
Formulation and in vitro evaluation of transdermal patches of melatonin. Drug Dev Ind Pharm (2004) 0.85
1,1-Bis (3'-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model. Eur J Pharm Sci (2013) 0.84
Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. Mol Pharm (2015) 0.84
Effect of cyclodextrins on the complexation and nasal permeation of melatonin. Drug Deliv (2008) 0.83
Inhalation delivery of anticancer agents via HFA-based metered dose inhaler using methotrexate as a model drug. J Aerosol Med (2002) 0.81
Preformulation stability of Spantide II, a promising topical anti-inflammatory agent for the treatment of psoriasis and contact dermatitis. J Pharm Pharmacol (2004) 0.81
Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers. J Biomed Nanotechnol (2015) 0.80
Chemoprevention of skin cancer with 1,1-Bis (3'-indolyl)-1-(aromatic) methane analog through induction of the orphan nuclear receptor, NR4A2 (Nurr1). PLoS One (2013) 0.80
Effect of monensin liposomes on the cytotoxicity of anti-My9-bR immunotoxin. J Pharm Pharmacol (2003) 0.80
EphA2 targeting pegylated nanocarrier drug delivery system for treatment of lung cancer. Pharm Res (2014) 0.80
Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res (2013) 0.79
In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm (EPI-200) cultured human skin and hairless rats. Toxicol Lett (2006) 0.79
Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. Toxicology (2007) 0.78
Dermal microdialysis of inflammatory markers induced by aliphatic hydrocarbons in rats. Toxicol Lett (2008) 0.78
Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (Lond) (2014) 0.78
Nose-to-brain transport of melatonin from polymer gel suspensions: a microdialysis study in rats. J Drug Target (2011) 0.78
Brownian diffusion and surface kinetics of liposome and viral particle uptake by human lung cancer cells in-vitro. Ann Biomed Eng (2006) 0.78
Epithelial transport of noscapine across cell monolayer and influence of absorption enhancers on in vitro permeation and bioavailability: implications for intestinal absorption. J Drug Target (2014) 0.77
Effect of jet fuels on the skin morphology and irritation in hairless rats. Toxicology (2002) 0.77
Opening up the optical imaging window using nano-luciferin. Pharm Res (2014) 0.77
Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM). Eur J Pharm Sci (2012) 0.77
Evaluation of Spray BIO-Max DIM-P in Dogs for Oral Bioavailability and in Nu/nu Mice Bearing Orthotopic/Metastatic Lung Tumor Models for Anticancer Activity. Pharm Res (2015) 0.76
Chapter 9 - Nanoliposomal dry powder formulations. Methods Enzymol (2009) 0.76
Enhanced Percutaneous Delivery of 1,1-bis(3'-indolyl)-1-(p-chlorophenyl) Methane for Skin Cancer Chemoprevention. J Biomed Nanotechnol (2015) 0.76
Stability and degradation profiles of Spantide II in aqueous solutions. Eur J Pharm Sci (2005) 0.76
Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. J Pharm Pharmacol (2004) 0.75
Steep atomic dispersion induced by velocity-selective optical pumping. Opt Express (2008) 0.75
Effect of combination of hydrophilic and lipophilic permeation enhancers on the skin permeation of kahalalide F. J Pharm Pharmacol (2014) 0.75
Evaluation of metered dose inhaler (MDI) formulations of ciclosporin. J Pharm Pharmacol (2007) 0.75